Variable | Overall Survival | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
P Value | HR | P Value | HR | |
Age at diagnosis (years) ≤70 vs >70 | 0.035 | 5.812 | 0.174 | ―― |
Gland volume (mL) ≤33 vs >33 | 0.006 | 3.816 | 0.042 | 1.192 |
MAB Continuous vs Intermittent | 0.583 | ―― | 0.457 | ―― |
PPB yes vs no | 0.007 | 3.016 | <0.001 | 6.358 |
Clinical stage ≤ T2c vs ≥T3a | <0.001 | 4.557 | 0.011 | 2.183 |
Gleason score ≤7 vs ≥8 | 0.001 | 3.356 | <0.001 | 7.142 |
PSA at diagnosis (ng/mL) ≤10 vs 10~20 vs ≥20 | 0.027 | 1.558 | 0.014 | 3.492 |
Memorial Sloan-Kettering risk classification 2~3 IS vs 1 HS vs 2 HS | <0.001 | 7.658 | <0.001 | 5.479 |
PSA nadir (ng/mL) ≤1 vs >1 | <0.001 | 9.473 | 0.012 | 4.553 |
Time to PSA nadir (months) ≤3 vs >3 | 0.012 | 3.113 | 0.038 | 1.249 |
PSA doubling time (months) ≤12 vs >12 | 0.042 | 2.665 | 0.028 | 5.511 |
PSA decrease (%) <90 vs ≥90 | <0.001 | 13.463 | <0.001 | 7.845 |